MaxCyte Financial Statements
NASDAQ: MXCTHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MaxCyte revenue and earnings
In fiscal 2025, MaxCyte generated $33.0 million in revenue, down 14.5% from fiscal 2024, its first annual decline since 2024. MaxCyte reported a net loss of $44.6 million, compared with a loss of $41.1 million a year earlier. Gross margin was 81.2% (down from 81.6%) and operating margin -157.1%.
Diluted earnings per share came in at -$0.42. Over the last 5 fiscal years, MXCT's revenue has grown at a 4.8% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
MaxCyte income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Revenue | 33.03M | 38.63M | 41.29M | 44.26M | 33.89M | 26.17M | 21.62M |
| Revenue growth (YoY) | -14.50% | -6.44% | -6.72% | +30.59% | +29.52% | +21.04% | — |
| Cost of Revenue | 6.22M | 7.10M | 4.74M | 5.10M | 3.65M | 2.77M | 2.50M |
| Gross Profit | 26.80M | 31.53M | 36.55M | 39.16M | 30.25M | 23.40M | 19.12M |
| Operating Expenses | 78.70M | 82.72M | 84.84M | 66.52M | 48.44M | 34.46M | 31.54M |
| Research & Development | 20.82M | 22.23M | 23.82M | 19.51M | 15.41M | 17.73M | 17.59M |
| Selling, General & Admin | 47.04M | 56.35M | 57.04M | 44.48M | 31.68M | 15.70M | 13.41M |
| Operating Income | -51.90M | -51.20M | -48.30M | -27.36M | -18.19M | -11.06M | -12.42M |
| Interest Expense | — | — | — | — | 5.40K | 21.70K | 51.90K |
| Other Income (Expense) | 7.27M | 10.14M | 10.38M | 3.79M | -893.60K | -759.70K | -475.00K |
| Pretax Income | -44.63M | -41.05M | -37.92M | — | — | — | — |
| Income Tax | — | — | — | — | 0 | 0 | 0 |
| Net Income | -44.63M | -41.05M | -37.92M | -23.57M | -19.08M | -11.82M | -12.89M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| EPS (Basic) | -0.42 | -0.39 | -0.37 | -0.23 | -0.21 | -0.17 | -0.23 |
| EPS (Diluted) | -0.42 | -0.39 | -0.37 | -0.23 | -0.21 | -0.17 | -0.23 |
| Shares Outstanding (Basic) | 106.43M | 104.85M | 103.27M | 101.70M | 90.62M | 69.46M | 56.40M |
| Shares Outstanding (Diluted) | 106.43M | 104.85M | 103.27M | 101.70M | 90.62M | 69.46M | 56.40M |
| EBITDA | -47.56M | -46.88M | -44.13M | -24.66M | -16.76M | -10.01M | -11.81M |
| Gross Margin | 81.16% | 81.62% | 88.51% | 88.48% | 89.24% | 89.43% | 88.44% |
| Operating Margin | -157.14% | -132.54% | -116.98% | -61.82% | -53.66% | -42.25% | -57.44% |
| Net Margin | -135.14% | -106.29% | -91.85% | -53.25% | -56.30% | -45.15% | -59.64% |
This table shows 7 annual periods of MaxCyte's income statement, from FY 2025 back to FY 2019, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow MXCT's reporting calendar. What is a income statement?